Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia

Dong, Weilai; Jin, Sheng Chih; Allocco, August; Zeng, Xue; Sheth, Amar H.; Panchagnula, Shreyas; Castonguay, Annie; Lorenzo, Louis-Étienne; Islam, Barira; Brindle, Geneviève; Bachand, Karine; Hu, Jamie; Sularz, Agata; Gaillard, Jonathan; Choi, Jungmin; Dunbar, Ashley; Nelson-Williams, Carol; Kiziltug, Emre; Furey, Charuta Gavankar; Conine, Sierra; Duy, Phan Q.; Kundishora, Adam J.; Loring, Erin; Li, Boyang; Lu, Qiongshi; Zhou, Geyu; Liu, Wei; Li, Xinyue; Sierant, Michael C.; Mane, Shrikant; Castaldi, Christopher; López-Giráldez, Francesc; Knight, James R.; Sekula, Raymond F.; Simard, J. Marc; Eskandar, Emad N.; Gottschalk, Christopher; Moliterno, Jennifer; Günel, Murat; Gerrard, Jason L.; Dib-Hajj, Sulayman; Waxman, Stephen G.; Barker, Fred G.; Alper, Seth L.; Chahine, Mohamed; Haider, Shozeb; De Koninck, Yves; Lifton, Richard P.; Kahle, Kristopher T.

Published in:
iScience

Published: 23/10/2020

Document Version:
Final Published version, also known as Publisher's PDF, Publisher's Final version or Version of Record

License:
CC BY-NC-ND

Published record in CityU Scholars:
Go to record

Published version (DOI):
10.1016/j.isci.2020.101552

Publication details:

Citing this paper
Please note that where the full-text provided on CityU Scholars is the Post-print version (also known as Accepted Author Manuscript, Peer-reviewed or Author Final version), it may differ from the Final Published version. When citing, ensure that you check and use the publisher's definitive version for pagination and other details.

General rights
Copyright for the publications made accessible via the CityU Scholars portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Users may not further distribute the material or use it for any profit-making activity or commercial gain.
Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia

1. Whole-exome sequencing of 290 TN Cases

2. Identification of rare variants in GABA signaling and ion channel genes

3. Generation of TN mouse model engineered with a human mutation

HIGHLIGHTS

- Genomic analysis of trigeminal neuralgia (TN) using exome sequencing
- Rare mutations in GABA signaling and ion transport genes are enriched in TN cases
- Generation of a genetic TN mouse model engineered with a patient-specific mutation
Trigeminal neuralgia (TN) is a common, debilitating neuropathic face pain syndrome characterized by recurrent, paroxysmal, lancinating pain in the distribution of the trigeminal nerve that is variably trigeminal in origin. The pathogenesis of TN is multifactorial, involving both genetic and environmental factors. Genetic factors have been implicated in the development of TN, with recent studies identifying variants in genes encoding proteins involved in neuronal ion transport as potential contributors to disease susceptibility. In this study, we performed exome sequencing on 290 TN probands and their parent-offspring trios to identify rare, damaging variants in genes encoding neuronal ion transport proteins. We identified a novel mutation in the GABAR gamma 1 subunit (GABRG1) in a TN proband, which was not observed in control individuals. This variant was transmitted to the proband’s offspring, providing evidence for its role in TN pathogenesis. Additionally, we observed enrichment of rare, damaging variants in other genes encoding neuronal ion transport proteins, including calcium channels and sodium channels. These results support the hypothesis that impaired GABA signaling and neuronal ion transport play a role in the development of TN. Further studies are needed to validate these findings and to elucidate the mechanisms by which these variants contribute to disease susceptibility.
lamotrigine, and topiramate (Ahmed et al., 2012). The efficacy of these drugs suggests that neuronal hyperexcitability and aberrant ion transport may be involved in TN pathogenesis. For patients resistant to medical therapy, alternative interventional and surgical treatments are offered. These include neurolysis of the trigeminal ganglion and the cisternal segment of the nerve, as well as open neurosurgical microvascular decompression (MVD) of the nerve. However, the few reported randomized, placebo-controlled trials with long-term follow-up have left continued uncertainty about the efficacy of these medical and surgical interventions (Zakrzewska and Akram, 2011). Gaps in our understanding of the cellular and molecular pathogenesis of TN have impeded the development of improved diagnostic, prognostic, and therapeutic measures.

The reported heritability of neuropathic pain conditions ranges from 16% to 50% (Hocking et al., 2012; Nielsen et al., 2012). Familial forms of TN are well documented, with many exhibiting autosomal dominant inheritance with incomplete penetrance (El Otmani et al., 2008; Rodriguez et al., 2019; Fleetwood et al., 2001; Smyth et al., 2003). The average age of onset in familial forms is 44.4 years (Fleetwood et al., 2001), 9 years younger than the average age of sporadic TN cases (Maa¨rberg et al., 2015). A subset of familial forms demonstrates genetic anticipation, with progressively earlier disease onset across each succeeding generation (Harris, 1936; Smyth et al., 2003). These observations implicate genetic determinants in TN pathogenesis. Previous studies using candidate gene approaches have identified an association of TN with a common SNP in the Na⁺-dependent serotonin transporter SERT (SLC6A4) (Cui et al., 2014) and a gain-of-function de novo mutation (DNM) in the voltage-gated Na⁺ channel NaV1.6 (SCN8A) in a single patient with TN (Tanaka et al., 2016). However, no large, unbiased, whole-exome sequencing (WES) genomics study of TN has been performed to date.

The discovery of human genetic variants associated with TN could illuminate disease mechanisms, explain the variability of TN phenotypes and therapeutic responses, and identify potential drug targets for therapeutic intervention. Here, we present our analysis of WES of 290 TN probands, including 20 multiplex inkindreds and 70 parent-offspring trios. This approach, proven to be successful for several neurodevelopmental disorders (Allen et al., 2013; Furey et al., 2018; Lossyov et al., 2012; Vissers et al., 2010), congenital heart disease (Jin et al., 2017; Zadi et al., 2013), and other heritable conditions (Duran et al., 2019; Furey et al., 2018; Timberlake et al., 2016), enables unbiased identification of rare, damaging DNM and copy number variations (CNVs), along with rare, inherited single-nucleotide variants and insertions and deletions (indels) that contribute to disease pathogenesis. We hypothesized that rare, damaging variants in genes encoding proteins with important roles in the development, structure, or function of neurons in the peripheral or central trigeminal pain circuitry might confer risk for the development of TN.

RESULTS
Cohort Characteristics and Whole-Exome Sequencing
We ascertained 290 probands with TN-related disorders, including 41 from the UK Biobank (Table 1). UK Biobank patients included 34 singleton probands (85.4%) with a primary diagnosis of TN (ICD10 code: G50.0), 6 singleton probands (17.1%) with atypical facial pain (ICD10 code: G50.1), and one singleton proband with both. We recruited an additional 249 probands with either cTN, iTN type 1 (purely paroxysmal) or type 2 (with concomitant continuous pain) that included 70 parent-offspring trios; 63.9% (159/249) of probands had undergone neurosurgical intervention, including MVD (54.6%, 136/249), thermal or balloon rhizotomy (11.6%, 29/249), or gamma knife radiosurgery (14.9%, 37/249). Of the patients treated with MVD, 42.6% (58/136) did not have sustained symptom relief; 19.1% (26/136) of these patients underwent a repeat MVD for post-operative recurrent or symptomatic responses. Interestingly, 36/249 (14.5%) cases were characterized by bilateral TN and 41/249 (16.5%) probands had a family history of TN.

Variants in Genes Previously Associated with TN
To gain insight into the genetic architecture of TN, we first screened for rare, damaging heterozygous mutations (minor allele frequency [MAF] \( \leq 1 \times 10^{-6} \)) in Bravo (Program, 2018) in genes previously implicated in TN (Cui et al., 2014; Tanaka et al., 2016). Two probands each carried a deleterious missense (predicted as deleterious by MetaSVM or having a CADD score \( \geq 30; \) D-mis) (Dong et al., 2015; Kircher et al., 2014) mutation in non-conserved residues of SCN8A. p.Ile1583Thr maps to the ion transport domain, and p.Arg475Gln is located immediately adjacent to the voltage-gated Na⁺ channel domain (Figures S1A and S1B). No rare damaging mutations were identified in SLC6A4.
We next examined rare (MAF ≤ 3%) damaging (i.e., D-mis or loss-of-function [LoF]) variants that segregated with TN in 20 multiplex families with at least two affected individuals available for WES (Figure 1). Of the 10 genes with segregating variants in at least two families (Table S1A), only SCN5A, encoding Na+ channel Nav1.5, was intolerant to both LoF (pLI ≥ 0.9) and missense variants (missense z-score ≥ 2) (Figures S1C and S1D). In iTN-1 family TRGN201, SCN5A p.Arg1826His was shared by affected siblings.

Table 1. Demographic and clinical characteristics of TN cases and controls
The number of samples is shown in each category with the corresponding percentage in parentheses. Some Trios contain ≥ 2 affected members. Ethnicity is determined by principal component analysis compared to HapMap samples using EIGENSTRAT. See also Figure S4.

<table>
<thead>
<tr>
<th></th>
<th>TN Cases from Yale</th>
<th>TN Cases from UK BioBank</th>
<th>Autism Sibling Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>249</td>
<td>41</td>
<td>1,798</td>
</tr>
<tr>
<td>Trios</td>
<td>70 (28.1%)</td>
<td>0 (0.0%)</td>
<td>1,798 (100.0%)</td>
</tr>
<tr>
<td>Non-trio cases</td>
<td>179 (71.9%)</td>
<td>41 (100.0%)</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Cases with family history of TN</td>
<td>41 (16.5%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Cases with ≥ 2 affected members sequenced</td>
<td>20 (8.0%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>34 (13.7%)</td>
<td>15 (36.6%)</td>
<td>842 (46.8%)</td>
</tr>
<tr>
<td>Female</td>
<td>215 (86.3%)</td>
<td>26 (63.4%)</td>
<td>956 (53.2%)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European</td>
<td>238 (95.6%)</td>
<td>38 (92.7%)</td>
<td>1,418 (78.9%)</td>
</tr>
<tr>
<td>African American</td>
<td>0 (0.0%)</td>
<td>1 (2.4%)</td>
<td>77 (4.3%)</td>
</tr>
<tr>
<td>East Asian</td>
<td>1 (0.4%)</td>
<td>1 (2.4%)</td>
<td>40 (2.2%)</td>
</tr>
<tr>
<td>South Asian</td>
<td>1 (0.4%)</td>
<td>0 (0.0%)</td>
<td>88 (4.9%)</td>
</tr>
<tr>
<td>Mexican</td>
<td>6 (2.4%)</td>
<td>1 (2.4%)</td>
<td>129 (7.2%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (1.2%)</td>
<td>0 (0.0%)</td>
<td>46 (2.6%)</td>
</tr>
<tr>
<td>TN type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cTN-1</td>
<td>47 (18.9%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>cTN-2</td>
<td>80 (32.1%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>iTN-1</td>
<td>44 (17.7%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>iTN-2</td>
<td>78 (31.3%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Bilateral symptoms</td>
<td>36 (14.5%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Neurosurgical intervention</td>
<td>159 (63.9%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>MVD</td>
<td>136 (54.6%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>With relief of symptoms</td>
<td>75 (30.1%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>No relief of symptoms</td>
<td>58 (23.3%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Repeated MVD</td>
<td>26 (10.4%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Thermal or balloon rhizotomy</td>
<td>29 (11.6%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Gamma knife</td>
<td>37 (14.9%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Other</td>
<td>22 (8.8%)</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Familial Forms of TN and SCN5A Variants
We next examined rare (MAF ≤ 5 x 10⁻⁵) damaging (i.e., D-mis or loss-of-function [LoF]) variants that segregated with TN in 20 multiplex families with at least two affected individuals available for WES (Figure 1). Of the 10 genes with segregating variants in at least two families (Table S1A), only SCN5A, encoding Na+ channel Nav1.5, was intolerant to both LoF (pLI ≥ 0.9) and missense variants (missense z-score ≥ 2) (Figures S1C and S1D). In iTN-1 family TRGN201, SCN5A p.Arg1826His was shared by affected siblings.
TRGN201-1 and TRGN201-2 (Figure S1E). p.Arg1826His maps to a conserved residue in the Nav1.5 C-terminal cytoplasmic domain and is reported in ClinVar as pathogenic for long QT syndrome (Figure S1D). Nav1.5 Arg1826His-mediated Na⁺ currents exhibit delayed inactivation and a 2- to 3-fold increase in late Na⁺ current (Ackerman et al., 2001; Wei et al., 2013).

SCN5A p.Phe1293Ser was shared by cTN-1 proband TRGN141-1 and her affected maternal grandmother TRGN141-4 (Figure S1E). p.Phe1293Ser maps to SCN5A domain III and is predicted to alter Nav1.5 structure (Figure S1D). Of note, SCN5A-mutant TN patients did not report a history of cardiac arrhythmias or sudden death (Roberts, 2006).

Copy Number Variation in Familial TN
We also identified four rare CNVs (MAF ≤ 1 × 10⁻³) that segregated in three multiplex TN families (Table S1B). Among them, one ~500-kb duplication covering the serine-threonine kinase MAPK3 was shared by the proband and the affected mother, but not the unaffected father in family TRGN190. MAPK3 has been previously implicated in the pathogenesis of multiple trigeminal pain models (Alter et al., 2010; Liverman et al., 2009; Smyth et al., 2003; Sun et al., 2019). Interestingly, the TRGN190 proband with the MAPK3 duplication was diagnosed with bilateral cTN-1 at 11 years of age and exhibited bilateral NVC on brain magnetic resonance imaging (MRI). The patient was treated with bilateral MVD, followed 1 year later by repeat bilateral MVD for symptom recurrence. The proband's mother, also with an MAPK3 duplication, was diagnosed with bilateral cTN-1 at 43 years of age. Although NVC was observed on her MRI, she declined surgery. Both patients reported significant symptom relief with the voltage-gated Na⁺ channel blocker oxcarbazepine. The proband's sister was also diagnosed with oxcarbazepine-responsive unilateral iTN at 17 years of age, but was not available for WES.

Rare, Damaging De Novo and Inherited Variants in GABA Signaling Genes
We next examined the contribution of DNMs, including CNVs, to TN risk. Our TN cohort demonstrated a rate of 1.06 coding region DNMs per proband, following the expected Poisson distribution and closely
match the burden of DNMs in the control cohort (Tables S2A and S2B). No genes contained more than one protein-altering DNM (Table S2C). Eleven de novo CNVs were identified, including a duplication in KCNK1, encoding the inward-rectifying K+ channel TWIK1 (Table S2D). Of note, pain insensitivity in multiple African rodents has been attributed in part to the down-regulation of kcnk1 expression (Eigenbrod et al., 2019). No recurrent CNVs were observed.

We performed Gene Ontology (GO) enrichment analysis (Raudvere et al., 2019) of genes harboring damaging DNMs with high brain expression (above 75% percentile among all genes from murine RNA sequencing) (Flegel et al., 2015). Analysis showed the greatest enrichment among genes associated with the molecular function term “GABA receptor binding genes” (GO:0050811) (GABRG1, TRAK1 [Figure 2A]; enrichment = 226.6, adjusted p value = 5.9 × 10^{-3} [Table S3A]). Damaging DNMs in GO:0050811 genes were enriched in TN cases but not in controls (enrichment = 114.0, p value = 1.5 × 10^{-3}) (Table S3B). Interestingly, several other notable genes with rare damaging DNMs but not included under the GO term GO:0050811 were identified that, similar to GABRG1 and TRAK1, have elevated brain expression and play important roles in GABA signaling or neurotransmission. These include ASTN2 (c.1736+2T > C)

**Figure 2. Damaging De Novo and Inherited Mutations in GABRG1 and TRAK1 in TN Probands**

(A) De novo and inherited mutations in GABRG1 and TRAK1. Pedigrees with Sanger-validated mutant bases marked on the chromatograms.

(B) Mapping of GABRG1 and TRAK1 mutations. GABRG1 p.Cys188Trp and p.Tyr178His impact conserved residues at the neurotransmitter-gated ligand-binding domain of GABRG1. TRAK1 p.Glu798Lys affects a conserved residue of the second kinesin-binding Milton domain, whereas TRAK1 p.Arg124Gln maps to a conserved residue of the HAP1_N domain.

(C) Structural modeling of GABRG1 p.Cys188Trp and p.Tyr178His mutations. p.Cys188 disulfide bonds with Cys202. Mutation to Trp188 disrupts this conserved disulfide bond with calculated $\Delta G = 3.8$ kcal/mol. In the midst of surrounding hydrophobic residues, the side chain hydroxyl of Tyr178 hydrogen bonds with the guanidinium side chain of Arg166, stabilizing interactions between their adjacent $\beta$-sheets. Disruption of this hydrogen bond by Arg mutation to His is predicted to destabilize $\Delta G$ by 1.7 kcal/mol.

(D) WT and mutant mice were examined for nocifensive withdrawal behavior following stimulation of the trigeminal nerve region in response to mechanical stimulation using a single von Frey filament (0.6 g). The y axis values represent average responses to three stimulations (on different days; +1 = presence of a stimulus-associated grooming response; −1 = absence of grooming behavior). The Mann-Whitney test was applied to assess statistical difference between WT and mutant mice. A Kruskal-Wallis test evaluated significant differences among all sub-groups: male and female WT and mutants. p value * < 0.05, ** < 0.01; *** < 1 × 10^{-3}, **** < 1 × 10^{-4}.

(E and F) Measurement of nociceptive withdrawal threshold using the using the Simplified Up-Down method (SUDO) (Bonin et al., 2014). (E) Graph showing withdrawal threshold results using an adaptation of the method to test in the region innervated by the trigeminal nerve (see Methods; Taylor et al., Pain, 2012). (F) Nociceptive withdrawal threshold in response to mechanical stimulation of the hind paw using calibrated von Frey filaments. p value ** < 0.01. See also Figures S1 and S2; Tables S1, S3, S4, and S6; and Videos S1, S2, S3, S4, S5, S6, S7, and S8.
GABRG1 encodes the γ-1 subunit of the heteromeric ligand-gated gamma-aminobutyric acid type A receptor (GABA\(_A\)-R) Cl\(^-\) channel. Patient TRGN124-1 with iTN-1 had a rare D-mis GABRG1 DNM (p.Cys188Tyr) in a conserved residue of the GABA\(_A\)-R γ-1 ligand-binding domain that is predicted to disrupt a disulfide bond with Cys202 (ΔDG = 3.8 kcal/mol) (Figures 2A–2C). Unrelated patient TRGN343-1 with iTN-2 carried a rare D-mis GABRG1 mutation p.Tyr178His (MAF = 8.2 × 10\(^{-5}\)), which also maps to a conserved residue in the ligand-binding domain and is predicted to disrupt a hydrogen bond between adjacent β-sheets (ΔDG = 1.7 kcal/mol) (Figures 2A–2C). Another patient with TN in the UK Biobank carried a rare stop-gain mutation in GABRG1 (p.Trp33*) located just before the ligand-binding domain.

TRAK1 encodes a kinesin adaptor protein that regulates the anterograde axonal transport of mitochondria and GABA\(_A\)-Rs (Barel et al., 2017). Patient TRGN261-1 with iTN-2 had a rare D-mis TRAK1 DNM (p.Glu798Lys) (Figure S2A) in a conserved residue of the second kinesin-binding Milton domain of TRAK1 (Figure S2B). Unrelated patient TRGN107-1 with cTN-1 carried the unphased heterozygous D-mis TRAK1 mutation (p.Arg124Gln) with an MAF just above our threshold (1.6 × 10\(^{-3}\)). p.Arg124Gln maps to a highly conserved residue in the TRAK1 HAPI\(_1\)-N domain (IPR006933) that directly participates in GABA\(_A\)-R trafficking in conjunction with kinesin (KIF) proteins (Gilbert et al., 2006). Recessive TRAK1 mutations cause early infantile epileptic encephalopathy (OMIM# 618201) (Barel et al., 2017), and Trak1 knockout mice exhibit severely reduced central nervous system (CNS) abundance of GABA\(_A\)-Rs (Gilbert et al., 2006).

A total of nine rare (MAF ≤ 1.0 × 10\(^{-3}\)) damaging de novo, transmitted, or unphased mutations were identified in GO:0050811 GABA receptor-binding genes, yielding enrichment compared with gnomAD controls (odds ratio [OR] = 3.3, one-tailed Fisher’s exact p value = 3.8 × 10\(^{-3}\); Tables S3C and S3D). These genes included GABA\(_A\)-R subunit α-5 GABRA5 and trafficking regulators PLCL1, JAKMIP1, and ARFGEF2. Extension of our search to the 21 genes encoding HGNC-designated GABA receptor subunits identified two additional rare, damaging heterozygous mutations in the GABA\(_A\)-R α-6 and β-1 ligand-binding domain that is predicted to disrupt a disulfide bond with Cys202 (ΔDG = 3.8 kcal/mol) (Figures 2A–2C). Unrelated patient TRGN343-1 with cTN-1 carried a rare D-mis GABRA5p.Glu107Gln in GABRA6 and GABRE (Figure S1G). GABRA5p.Glu107Gln and GABRA6p.Glu90Ala both map to respective ligand-binding domains, whereas GABRE p.Trp300* affects the neurotransmitter gating domain (Figures S1H–S1J).

**Mouse Model of TN Engineered with a Patient-Specific GABRG1 Mutation**

As proof of principle, we generated a mouse model of one of the identified human TN-associated GABA\(_A\)-R DNNs (GABRG1 p.Cys188Tyr), using Crispr/CAS9 mutagenesis (Figure S2). To test for trigeminal pain hypersensitivity, we quantified nociceptive behaviors using a modified version of a facial stimulation test (Bailey and Ribeiro-da-Silva, 2006). In contrast to wild-type littermates (n = 23 mice), mutant mice (n = 25) showed significant nociceptive behaviors in response to tactile stimulation of the trigeminal nerve region (Figure 2D; p value < 1 × 10\(^{-3}\); Mann-Whitney test; Videos S1, S2, S3, S4, S5, S6, S7, and S8 and Table S4A) in both males (n = 11 wild-type and 12 mutants) and females (n = 12 wild-type and 13 mutants; p value = 0.045 for females; p value = 9 × 10\(^{-4}\) for males; Kruskal-Wallis test). No significant difference in nociceptive behavior was observed between male and female mutants (p value = 0.40). To measure nociceptive withdrawal threshold, we also used a modified mechanical threshold test (Bonin et al., 2014; Taylor et al., 2012). Mutant mice (n = 11) showed a significantly lower nociceptive withdrawal threshold than wild-types (n = 9; p value = 1.0 × 10\(^{-3}\); Mann-Whitney test Figure 2E and Table S4B). Hind paw nociceptive withdrawal threshold was also significantly reduced in mutant mice (p value = 1.6 × 10\(^{-3}\); Figures 2F and Table S4B).

**Significant Burden of Inherited and Unphased CACNA1H Variants**

Next, we performed burden analysis of rare de novo and inherited/unphased variants in 290 TN probands, adjusting for de novo mutability using a one-tailed binomial test. Analysis of ultra-rare variants at MAF ≤ 1 × 10\(^{-3}\) did not identify significantly enriched genes. However, among moderately rare variants at MAF ≤ 1 × 10\(^{-4}\), the Cav3.2 T-type Ca\(^{2+}\) channel α-1H subunit (CACNA1H) reached genome-wide significant enrichment in cases (enrichment = 3.7, p value = 2.4 × 10\(^{-6}\); Figure 3A and Table S5A). CACNA1H contained 19 predicted damaging variants, including one LoF variant and 18 D-mis variants (Table S5B). Among these, 16 are unphased and 3 are transmitted with incomplete penetrance. The CACNA1H variants

(Behesti et al., 2018), EEF2 (p.Arg839His) (Heise et al., 2017), UNC80 (p.Lys2794*) (Philippart and Khaliq, 2018; Yeh et al., 2008), and KIF1B (p.Arg928Trp) (Aulchenko et al., 2008; Lyons et al., 2009; Zuchner et al., 2004).
map to extracellular, intracellular, and intra-membrane regions of the ion channel (Figure 3B) and are predicted to impact Cav3.2 protein structure (Figures S3A–S3N). In one family, the CACNA1H D-mis variant p.Arg1674His was shared by proband TRGN282-1 and his sister TRGN282-2, both similarly affected by medically intractable iTN.

Identification of Hemizygous Variants in CACNA1F

Lastly, we examined recessive and hemizygous genotypes. No genes harbored more than one recessive genotype in 249 TN probands. However, case-control analysis comparing rare damaging hemizygous variants (MAF % $\leq 3\times 10^{-4}$) in 49 male TN probands with male controls in gnomAD identified CACNA1F, encoding the Cav3.2 T-type Ca$^{2+}$ channel α-1H subunit, as the most significantly enriched gene (OR = 12.0, p value $= 2.43\times 10^{-3}$; Table S5C). CACNA1F contained three rare D-mis variants (Figure 3C and Table SSD). p.Ala1335Thr and p.Arg1289Gly, respectively, mapped to the exofacial and endofacial surfaces of the channel. p.Ile721Val mapped to an extracellular loop of the channel. All three variants are predicted to significantly impact CACNA1F channel structure (Figures S3O–S3T).

DISCUSSION

These results provide insight into the genomic architecture of TN. We ascertained the largest collection of familial forms of TN to date and identified several candidate genes with mutational enrichment in TN probands. Our findings implicate de novo and inherited rare, damaging variants in GABA signaling and other ion transport genes in TN pathogenesis in a subset of patients. Our creation of a knock-in mouse with the TN-associated de novo GABRG1 p.Cys188Trp mutation represents an important attempt to engineer a TN animal model with a human mutation.

Previous candidate gene sequencing approaches had identified SCN8A and SLC6A4 as potential TN-associated genes (Cui et al., 2014; Tanaka et al., 2016). In our WES study, we detected only two rare transmitted mutations in SCN8A and none in SLC6A4. Nonetheless, our data implicate other ion transport pathways in the genetic architecture of TN, including genes related to the function of the ligand-gated GABA$_{A}$R Cl$^{-}$ channel. These findings are consistent with the expression of GABA$_{A}$Rs along sensory axons (Bhishikul et al., 1990; Oyelese et al., 1997), with the well-documented role of GABA$_{A}$R signaling in trigeminal pathway nociception (Dieb and Hafidi, 2015; Jang et al., 2017; Kaushal et al., 2016; Martin et al., 2010; Wei et al., 2013), with the efficacy of GABA-modulating drugs in some patients with TN (Granger et al., 1995; White et al., 2000) (Table S6), and with the established importance of GABA$_{A}$R disinhibition and consequent neuronal hyperexcitability in neuropathic pain (Dieb and Hafidi, 2015; Jang et al., 2017; Martin et al., 2010). These observations support our speculation that frequent co-occurrence of anxiety, depression, and other psychiatric conditions with TN, especially those in younger patients (Mousavi et al., 2016) (often
unresponsive to MVD) (Hamlyn, 1997a), may reflect pleiotropy of germline variants impacting other aspects of GABA signaling.

In addition to variants in GABA signaling genes, we also identified rare dominant variants in the SCN8A-related Nav1.5 Na⁺ channel gene SCN5A in two multiplex TN families, a genome-wide significant enrichment of rare dominant variants in the Ca₃.2 α-1H subunit CACNA1H and multiple rare X-linked hemizygous variants in the related Ca₃.2 α-1F subunit CACNA1F. Not only are SCNSA mutations well known to cause cardiac rhythm disorders including long QT syndrome subtype 3, Brugada syndrome, and cardiac conduction disease (Zimmer and Surber, 2008), but they are also expressed in the brain (Kerr et al., 2004) and have been implicated in both epilepsy (Parisi et al., 2013) and schizophrenia (Roberts, 2006). CACNA1H variants have been previously implicated in congenital pain (Souza et al., 2016) and epilepsy (Eckle et al., 2014). T-type Ca²⁺ currents mediated by Ca₃.2/α-1H are activated during GABAA R-mediated depolarizations and subsequently trigger action potential in sensory neurons (Aptel et al., 2007) and mechanosensation in nerve root ganglia (Shin et al., 2003). Increased expression of Ca₃.2 in damaged dorsal root ganglion neurons contributes to the development of neuropathic pain triggered by spared nerve injury (Kang et al., 2018). The closely-related Ca₃.1 has been shown to be a key element in the pathophysiology of a mouse model of trigeminal neuropathic pain (Choi et al., 2016). Mechanical thresholds of pain are significantly altered in a rat model of congenital stationary night blindness with a Cacna1f mutation (An et al., 2012). Detailed electrophysiology of these TN-associated SCNSA, CACNA1H, and CACNA1F channel variants in cell culture systems and animal models will be rich topics for future investigation.

How might these mutations and other gene variants contribute to TN pathology? One possibility is a “genetic-mechanical” model, in which a germline mutation confers increased sensitivity to the trigeminal ganglia or axons to NVC by an offending blood vessel, such as the superior cerebellar artery in the cerebello-pontine angle. This mechanism may contribute to unilaterality of symptoms in some patients with NVC and has been proposed for a gain-of-function mutation in SCN8A (Tanaka et al., 2016). A germline mutation could also predispose patients to the development of bilateral symptoms, as is seen in some patients with TN. Alternatively, a germline mutation could predispose an individual to later-onset TN arising from a second somatic mutation in the other allele of the same, or another, gene, in trigeminal ganglion neurons or other downstream brainstem or thalamo-cortical projection neurons in the trigeminal system circuitry. Such a “two-hit” model has been seen in other neurovascular cutaneous syndromes with unilateral or multifocal lesions (Brouillard et al., 2002; Pagenstecher et al., 2009; Revencu et al., 2013).

Our data suggest that rare, damaging exonic variants with large effect likely contribute to the pathogenesis of a small fraction of TN cases. Nonetheless, the investigation of such rare variants, especially DNMs, is a proven strategy to gain insight into disease pathogenesis. Therefore, continued gene discovery and functional analysis, including mechanistic work and drug screening in humanized animal models such as our GABRG1 p.Cys188Trp knock-in mouse, could further elucidate TN pathophysiology, improve diagnostics, and optimally stratify certain patients for specific treatments (e.g., a GABA-modulating drug instead of a craniotomy for MVD). Moreover, the identification of rare, damaging mutations with large effect (even in single patients) has the potential to identify unexpected targets for the development of non-addictive analgesics that could have broader relevance for other neuropathic pain syndromes (Yekkirala et al., 2017). Our findings suggest a WES approach might also be suitable to study hemifacial spasm, another cranial nerve pain syndrome with known familial occurrences that has been classically attributed to NVC and treated with neurosurgical MVD (Campbell and Keedy, 1947; Carter et al., 1990; Coad et al., 1991; Friedman et al., 1989; Hailer et al., 2016; Lagaila et al., 2010; Miwa et al., 2002).

Limitations of the Study

A limitation of our study, necessary given our article’s genomic focus and the magnitude of the effort, time, and expense required for patient recruitment, phenotyping, and bioinformatic analysis, is our lack of functional and mechanistic follow-up. In future work, the functional consequences of the identified mutations on channel or protein function using electrophysiological techniques in heterologous expression systems, or even better, model organisms with engineered patient mutations (starting with our GABRG1 mutant mouse), will be required. In these models, it will be important to establish the effect of mutated proteins on trigeminal pain circuitry; the expression of some of our mutated proteins in second- or higher-order neurons of the trigeminal nucleus suggests that CNS defects might contribute to pathology. Our current genomics article sets a foundation for these detailed functional studies.
Another limitation of our study is its focus on the role of rare coding variants. Given the impact of common variants in multiple neuropathic pain disorders (Gormley et al., 2018; Meng et al., 2015a, 2015b), we examined the contribution to TN from common variants through a genome-wide association analysis of 236 European cases and 348,028 ethnicity-matching controls from the UK Biobank. No common variants reached genome-wide significance (Figures S4A and S4B). However, the small number of available cases limited the power of our analysis. A power calculation suggests that ~1,600 cases are needed to achieve 80% power assuming moderate effect size (δ = 1.3) and an MAF of 0.2 for risk alleles (Figure S4C). Our analysis for these variants is thus underpowered. Future studies examining common variants will require a greater numbers of TN probands.

Although childhood and adolescent onset of TN has been reported (Bahgat et al., 2011), the high prevalence of TN and its inconsistent segregation patterns within families suggests that complex epistatic interactions, gene-environment interactions, or effects from common polygenic variants could also play important pathogenic roles in TN (Gormley et al., 2018; Zorina-Lichtenwalter et al., 2018). Addressing these questions will be important and challenging topics of future investigations.

Resource Availability

Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact (kristopher.kahle@yale.edu).

Materials Availability
No plasmids were generated in this study. Mouse lines generated in this study will be deposited to the Knockout Mouse Project (KOMP) and are available upon request.

Data and Code Availability
The WES data generated during this study are available at dbGap with accession number phs000744. Original data for the mouse experiments in Figures 2D–2F in the article are available at Table S4. Our in-house Python and R pipelines are available from the corresponding author on request.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101552.

ACKNOWLEDGMENTS

We thank the patients and families who participated in this research. We acknowledge Dr. Hongyu Zhao from the Department of Biostatistics, Yale School of Public Health for his mentorship on the statistical analysis and providing access to the UK Biobank Resource under Application Number 29900. We acknowledge support from the Yale-NIH Center for Mendelian Genomics (SU54HG006504) and an NIH NRCDP award to K.T.K. We acknowledge the Canadian Institute of Health Research (CIHR) Foundation grant (FDN389050) to Y.D.K. and CIHR grant (MOP-111072 and MOP-130373) to M.C. We acknowledge Dr. Kaya Bilguvar for his help on exome sequencing for the samples at Yale-NIH Center for Mendelian Genomics. W.D. was supported by American Heart Association Predoctoral Fellowship (19PRE34380842). S.C.J. was supported by the James Hudson Brown-Alexander Brown Coxe Postdoctoral Fellowship. S.C.J. was also supported by the Canadian Institute of Health Research (CIHR) Foundation grant (FDN389050) to Y.D.K. and CIHR grant (MOP-111072 and MOP-130373) to M.C. We acknowledge Dr. Kaya Bilguvar for his help on exome sequencing for the samples at Yale-NIH Center for Mendelian Genomics. W.D. was supported by American Heart Association Predoctoral Fellowship (19PRE34380842). S.C.J. was also supported by the James Hudson Brown-Alexander Brown Coxe Postdoctoral Fellowship (18POST34060008), and the K99/R00 Pathway to Independence Award (K99HL143036 and R00HL143036-02). Y.D.K. was supported by a Canada Research Chair in Chronic Pain and Related Brain Disorders.

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: June 18, 2020
Revised: September 6, 2020
Accepted: September 8, 2020
Published: October 23, 2020

REFERENCES
CACNA1H mutation in epilepsy patients increases seizure susceptibility. J. Physiol. 592, 795–809.


Supplemental Information

Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia

Figure S1. Mutations in known TN gene SCN8A, sodium channel gene SCN5A, and GABA receptor subunit genes GABRA5, GABRA6, and GABRE, related to Figure 1.2. (a) Variant information for SCN8A p.Arg475Gln and p.Ile1583Thr. (b) SCN8A contains four homologous domains I to IV, each containing 6 transmembrane segments. p.Arg475Gln is located at cytoplasmic loop 1; p.Ile1583Thr mapped to cytoplasmic portion between segment 1 and 2 of the the IV domain. (c) Variant information for SCN5A p.Phe1293Ser and p.Arg1826His. (d) Mutation mapping of SCN5A. SCN5A contains four homologous domains I to IV, each containing 6 transmembrane segments. p.Phe1293Ser mapped to an extracellular loop of domain III while p.Arg1826His located to the C-terminal cytoplasmic domain. (e) Pedigrees of the two families with inherited SCN5A mutations. Sample IDs indicate samples with WES. (f) Modeled structures of regions surrounding wildtype Phe1293 (left) and mutant Phe1293Ser (right). Phe1293 is a conserved residue, positioned in an exofacial hydrophobic pocket between helices S3 and S4, plausibly interacts with the membrane. Mutation to a polar Serine residue would be thermodynamically unfavourable in this hydrophobic environment (\(\Delta \Delta G = 0.34 \text{ kcal/mol}\)). Arg1826His variant could not be modelled due to absence of template. (g) GABRA5, GABRA6 and GABRE each contain a neurotransmitter-gated ion channel ligand-binding domain and a neurotransmitter-gated ion channel transmembrane region. Mutation mapping for (h) GABRA5 p.Glu107Gln and (i) GABRA6 p.Glu90Ala in the ligand binding domain, and (j) GABRE p.Trp300* in the transmembrane region. LBD: ligand-binding domain; Trans: transmembrane region.

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRGN136-1</td>
<td>SCN8A</td>
<td>D-mis</td>
<td>p.Ile1583Thr</td>
<td>2.15E+04</td>
<td>D</td>
<td>12.24</td>
</tr>
<tr>
<td>2890541</td>
<td></td>
<td>D-mis</td>
<td>p.Arg475Gln</td>
<td>3.27E+04</td>
<td>D</td>
<td>23.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4922269</td>
<td>GABRA5</td>
<td>D-mis</td>
<td>p.Glu107Gln</td>
<td>Novel</td>
<td>D</td>
<td>25.3</td>
</tr>
<tr>
<td>TRGN107-1</td>
<td>GABRA6</td>
<td>D-mis</td>
<td>p.Glu90Ala</td>
<td>Novel</td>
<td>D</td>
<td>25.7</td>
</tr>
<tr>
<td>TRGN231-1</td>
<td>GABRE</td>
<td>stopgain</td>
<td>p.Trp300*</td>
<td>Novel</td>
<td>NA</td>
<td>42.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>506 aa</td>
<td>LBD</td>
<td>Trans</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>453 aa</td>
<td>LBD</td>
<td>Trans</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>515 aa</td>
<td>LBD</td>
<td>Trans</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family ID</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRGN141</td>
<td>D-mis</td>
<td>p.Phe1293Ser</td>
<td>2.95E+04</td>
<td>D</td>
<td>23.7</td>
</tr>
<tr>
<td>TRGN201</td>
<td>D-mis</td>
<td>p.Arg1826His</td>
<td>1.83E+04</td>
<td>D</td>
<td>34.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GABRA5</td>
<td>D-mis</td>
<td>p.Glu107Gln</td>
<td>Novel</td>
<td>D</td>
<td>25.3</td>
</tr>
<tr>
<td></td>
<td>GABRA6</td>
<td>D-mis</td>
<td>p.Glu90Ala</td>
<td>Novel</td>
<td>D</td>
<td>25.7</td>
</tr>
<tr>
<td></td>
<td>GABRE</td>
<td>stopgain</td>
<td>p.Trp300*</td>
<td>Novel</td>
<td>NA</td>
<td>42.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ID</th>
<th>Gene</th>
<th>Mutation type</th>
<th>AA Change</th>
<th>Bravo</th>
<th>MetaSVM</th>
<th>CADD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure S2. Generation of Gabbr1 knock-in allele, related to Figure 2. (a) Schematic of the Cas9/sgRNA/oligo-targeting site in exon 5. The 20bp sgRNA coding sequence is in red. The PAM (protospacer adjacent motif) sequence is in green. Four base changes were made, one for the cysteine to tryptophan conversion, a silent change to disrupt the PAM (protospacer adjacent motif) and prevent re-cutting of the repaired DNA sequence, and two additional silent changes to generate a diagnostic PstI site. The mutated bases at oligo donor sequence are in boldface. (b) PCR products from genotyping of mice with homozygous allele using the following sequencing primers (F5′ – AGGAGGTCCAAATGCTGTT and R5′ – GGGAAGGGCGGTAGATG). Sequence across target region confirmed correct introduction of mutations. Red arrows: mutation loci.
Figure 3. Structural modelling of CACNA1H and CACNA1F variants, related to Figure 3. (a–n) CACNA1H variants. S187L (a) wild-type and (b) mutated. The hydroxyl group in Ser187 can form hydrogen bond interactions with the backbone carbonyl oxygen atoms of M183 and M184. Mutation to a hydrophobic L187 disrupts these interactions (ΔΔG = 0.12 kcal/mol). E286K (c) wild-type and (d) mutated. A protonated H355 can form a hydrogen bond with E286. However, the lysyl chain of K286 is too bulky for that site. Additionally there would be a positive charge repulsion between the side chain resulting in destabilization of the region (ΔΔG = 4.62 kcal/mol). A802V (e) wild-type and (f) mutated. A802 positioned between two helices is surrounded by hydrophobic residues. The larger side chain of V802 can alter nearby helical packing (ΔΔG = 2.06 kcal/mol). E819K (g) wild-type and (h) mutated. Several negatively charged amino acids are clustered around E819. The mutation to a positively charged lysine alters the surface electrostatic charge, potentially destabilizing local secondary structure (ΔΔG = 0.96 kcal/mol). P1605H (i) wild-type and (j) mutated. P1605 positioned at the end of a helix introduces a kink that cannot be replicated by the substituted His residue. R1674H (k) wild-type and (l) mutated. R1674 forms an ion pair with E1865. The ion pair is weakened and may be rendered pH-dependent, likely altering local structure (ΔΔG = 0.53 kcal/mol). R1736C (m) wild-type and (n) mutated. The guanidinium side chain of R1736 forms three hydrogen bonds to the backbone carbonyl oxygens of K1730, L1666 and K1667, and L1668. Loss of these interactions in the R1736 mutant greatly destabilizes the local structure (ΔΔG = 6.79 kcal/mol). The other variants could not be modelled due to absence of template. (o–t) CACNA1F variants. I721V (o) wild-type and (p) mutated. I721 lies in a shallow hydrophobic pocket and forms van der Waals interactions with I310, M717 and M732. The strength of the interactions with these residues, especially M717, will be reduced for valine, as its side chain is smaller than that of isoleucine (ΔΔG = 0.78 kcal/mol). R1289G (q) wild-type and (r) mutated. R1289 tethers a helix to a loop by making an ion pair interaction with D1223. Mutation to glycine will disrupt the interactions and change the shape of the loop (ΔΔG = 1.04 kcal/mol). A1335T (s) wild-type and (t) mutated. A1335 lies in the middle in a hydrophobic region in the middle of a helix. Mutation to a polar residue as threonine will change the environment and modestly destabilize the helix (ΔΔG = 0.62 kcal/mol).
Figure S4. Gnome-wide association analysis (GWAS) and power calculation, related to Table 1. (a-b) GWAS of 236 European cases with TN and 348,028 ethnicity-matched controls from UK Biobank. (a) Manhattan plot for p-values resulting from GWAS. (b) Quantile-quantile plot of observed versus expected p-values. No variants reach genome-wide significance ($P < 5 \times 10^{-8}$). (c) Power calculation for GWAS of trigeminal neuralgia. Assuming a population prevalence of disease of 0.2%, the graphs show calculated power under lambda = 1.1, 1.2, 1.3, 1.4 at different minor allele frequencies and sample sizes (half of the samples are cases and half are controls).
TRANSPARENT METHODS

Case cohort, enrollment, phenotyping, and exclusion criteria

249 probands and their relatives for this study were ascertained from the Yale Facial Pain Clinic; from collaborating institutions; or by responding to a study invitation posted on social media. Written informed consent for genetic studies was obtained from all participants. Parent or legal guardian authorization was obtained in writing for sample collection of all minors in this study. All study protocols were approved by the Yale Human Research Protection Program and Institutional Review Board. Patients and participating family members provided buccal swab samples (Isohelix SK-2S DNA buccal swab kits), medical records, radiological imaging studies and official written reports, and neurosurgery operative reports when available. Inclusion criteria included a diagnosis of either classical trigeminal neuralgia (13.1.1.1) or idiopathic trigeminal neuralgia (13.1.1.3) (Society, 2018) by a neurologist or neurosurgeon. Participants were further subdivided into either “13.1.1.1.1 Classical TN, purely paroxysmal” (“cTN-1”) and “13.1.1.1.2 Classical TN with concomitant continuous pain” (“cTN-2”), or “13.1.1.3.1 Idiopathic TN, purely paroxysmal” (“iTN-1”) and “13.1.1.3.2 Idiopathic TN with concomitant continuous pain” (“iTN-1”), according to ICHD-3 criteria (Society, 2018) based on phenotypic data. By definition, “13.1.1.2 Secondary TN”, including “13.1.1.2.1 TN attributed to multiple sclerosis”, “13.1.1.2.2 TN attributed to space-occupying lesion”, “13.1.1.2.3 TN attributed to other cause”, and “13.1.2 Painful trigeminal neuropathy” related to previous trauma, surgery, or radiation to the trigeminal nerve ipsilateral to pain were excluded from analysis. Also excluded were patients with psychiatric or mental illness that might interfere with patients’ ability to grant informed consent or to complete clinical questionnaires.

41 probands with available WES were acquired from UK Biobank with either trigeminal neuralgia (ICD10 code: G50.0) or atypical facial pain (ICD10 code: G50.1) as main diagnosis.

Control cohorts

Controls consisted of 1,798 previously analyzed families with one offspring with autism, one unaffected sibling, and unaffected parents. In this study only the unaffected sibling and parents were analyzed. Controls were designated as unaffected by SSC (Krumm et al., 2015). Permission to access SCC genomic data in the National Institute of Mental Health Data Repository was obtained. Written informed consent for all participants was provided by the Simons Foundation Autism Research Initiative.

Exome sequencing

249 probands and their relatives were sequenced at the Yale Center for Genome Analysis following the same protocol. Briefly, genomic DNA from venous blood or saliva was captured using the Nimblegen SeqxCap EZ MedExome Target Enrichment Kit (Roche) or the xGEN Exome Research Panel v1.0 (IDT) followed by Illumina DNA sequencing (Furey et al., 2018). All Yale and UK Biobank samples were analyzed with the same pipeline. At each site sequence reads were independently mapped to the reference genome (GRCh37) with BWA-MEM and further processed using GATK Best Practices workflows (Genomes Project et al., 2015; McKenna et al., 2010; Van
der Auwera et al., 2013) including duplication marking, indel realignment, and base quality recalibration. Single nucleotide variants and small indels were called using GATK HaplotyperCaller and Freebayes (Garrison E, 2012) and annotated using ANNOVAR (Wang et al., 2010), dbSNP (v138), 1000 Genomes (August 2015)(Genomes Project et al., 2015), NHLBI Exome Variant Server (EVS; https://evs.gs.washington.edu/EVS/), ExAC (v3) (Lek et al., 2016) and Bravo (Program, 2018). The MetaSVM and the Combined Annotation Dependent Deletion (CADD) algorithms were used to predict deleteriousness of missense variants (“D-mis”, defined as MetaSVM-deleterious or CADD ≥30) (Dong et al., 2015; Kircher et al., 2014). Candidate variant calls were validated using Sanger sequencing.

**Kinship analysis and removal of duplicated samples**

Pedigree information and participant relationships were confirmed using pairwise PLINK identity-by-descent (IBD) calculation (Purcell et al., 2007) and pairwise comparison of high quality ultra-rare SNPs absent from public databases (ExAC and gnomAD)(Lek et al., 2016). Individuals with ≥ 90% IBD or shared ultra-rare SNPs were identified as sample duplicates and removed from analysis.

**Principal component analysis**

EIGENSTAT software (Price et al., 2006) was used to classify ethnicities through analyzing tag SNPs in cases and HapMap samples with known ethnicities. Principal component analysis was then performed to cluster the studied samples with HapMap samples using R software (version 3.4.1) (Wang et al., 2014), and the ethnicities of the cases were determined based on their best clustered ethnicity group against HapMap populations.

**Variant filtering**

DNMs were called using TrioDenovo (Wei et al., 2015) and filtered using stringent hard cutoffs including: (1) in-cohort allele frequency ≤ 4 × 10^{-4} for controls and MAF ≤ 4 × 10^{-4} across all samples in 1000 Genomes, EVS, and ExAC, Bravo for cases due to limited cohort size, (2) a minimum of 10 total reads total, 5 alternative allele reads, and a minimum of 20% alternate allele ratio in the proband for alternate allele reads ≥ 10 or for alternate allele reads < 10, a minimum 28% alternate ratio, (3) a minimum depth of 10 reference reads and alternate allele ratio < 3.5% in parents, and (4) exonic or canonical splice-site variants.

For transmitted heterozygous variants, we filtered for high-quality heterozygotes (pass GATK Variant Score Quality Recalibration [VQSR], minimum 8 total reads, and genotype quality [GQ] score ≥ 20)(Genomes Project et al., 2015; Lek et al., 2016). Variants with large impact on protein structures including LoF (canonical splice-site, frameshift insertion/deletion, stop-gain, stop-loss) and D-mis variants were considered for the analysis. Common variants with MAF > 5×10^{-3} within the cohort were excluded. Rare variants with MAF ≤ 1×10^{-3} in Bravo were screened in known TN genes. Both ultra-rare (MAF ≤ 1×10^{-5} in Bravo) and moderately rare (MAF ≤ 1×10^{-4} in Bravo) variants were tested for enrichment across all genes of the genome.
We filtered recessive variants for rare (MAF ≤ 10⁻³ in Bravo and in-cohort MAF ≤ 5×10⁻³) homozygous and compound heterozygous variants that exhibited high quality sequence reads (pass GATK VSQR, have ≥ 4 total reads for homozygous and ≥ 8 reads for compound heterozygous variants, have a GQ ≥ 10 for homozygous and GQ ≥ 20 for compound heterozygous variants). Only LoF, D-mis, and non-frameshift indels were considered potentially damaging to the disease.

Hemizygous variants were filtered by the same criteria as were recessive variants except for a more stringent frequency filter (MAF ≤ 5×10⁻⁵ in Bravo and in-cohort MAF ≤ 5×10⁻³).

Segregated variants in familial cases were filtered for rare (MAF ≤ 5×10⁻⁴ in Bravo and in-cohort MAF ≤ 5×10⁻³) and damaging (LoF and D-mis) dominant variants shared by affected individuals.

Finally, in silico visualization was performed on all de novo, heterozygous, recessive variants, and hemizygous variants that (1) appeared at least twice, (2) were among the top 20 significant genes from the burden analysis, or (3) segregated in the families. Sanger validation was performed on candidate variants of interest.

**De novo enrichment analysis**

The expected number of DNM per gene per variant class was obtained based on a mutation model developed previously (Samocha et al., 2014). A one-tail Poisson test was used to compare the observed number of DNMs across each variant class to the expected number under the null hypothesis. The R package ‘denovolyzeR’ (Ware et al., 2015) was used to perform all de novo analyses.

**Gene Ontology Enrichment Analysis**

Functional profiling of 10 genes with high brain expression (brain expression rank ≥ 75%) (Flegel et al., 2015) harboring DNMs was conducted with g:GOSt from g:Profiler (Raudvere et al., 2019), a tool that performs gene set overrepresentation/enrichment analysis and detects statistically enriched terms from functional information sources, including the Gene Ontology database (Ashburner et al., 2000; The Gene Ontology, 2019). We used all annotated genes as the statistical domain scope, the g:SCS algorithm (Raudvere et al., 2019) to address multiple testing, and p = 0.05 as a user-defined threshold for statistical significance.

**Case-control burden analysis**

Case and control cohorts were processed using the same pipeline and filtered with the same criteria (see Variant filtering section). A one-sided Fisher’s exact test was used to compare the observed number of mutations in each variant class examined in cases to the same variant class in controls under the null hypothesis. The gnomAD controls we used are without TOPMed samples.

**Copy number variation analysis**

To identify CNVs from WES data, the aligned reads were imported into XHMM (eXome-Hidden Markov Model) (Fromer et al., 2012). Potential CNVs were inspected visually and prioritized...
based on Phred-scaled quality score (SQ ≥ 90), genomic length, GC content of targets, and low sequence complexity. CNVs were further annotated by their MAF in gnomAD and 1000 genome databases. Only rare CNVs with MAF ≤ 1×10⁻³ in the above two databases were kept.

**Protein structural modelling**

The sequence of human SCN5A protein was downloaded from UniProt (Q14524) and aligned with the cryo-electron microscopy structure of the human Nav1.2-beta2-KIIIA (PDB: 6J8E, resolution: 3.00 Å) in ICM-Molsoft (Abagyan et al., 1994; Pan et al., 2019). The homology model was built in ICM-Molsoft based on an 80% sequence identity over resolved residues of human Nav1.2-beta2-KIIIA complex.

The sequence of human CACNA1H protein was downloaded from UniProt (O95180). The structures of the human Cav3.1 (PDB: 6KZO, resolution 3.3 Å) and rabbit Cav1.1 complex (PDB: 5GJW, resolution: 3.6 Å) were used to model the protein using homology tool of ICM-Pro (Wu et al., 2016; Zhao et al., 2019). The initial model was built based on an 85% sequence identity over the resolved residues of human Cav3.1. As the homologous sequence for the loop harbouring residue of interest (R1674) and the surrounding region between 1562-1619 residues were missing in the structure of human Cav3.1, it was built using rabbit Cav1.1 as the template.

The sequence of human CACNA1F protein was downloaded from UniProt (O60840) and aligned with the cryo-electron microscopy structure of the rabbit Cav1.1 complex (PDB: 5GJV, resolution: 3.6 Å) in MolSoft ICM-Pro ver 1.8.7c (Abagyan et al., 1994; Wu et al., 2016). The homology model was built in ICM-Pro based on a 75% sequence identity over the resolved residues of rabbit Cav1.1 complex. All the investigated residues lie in the conserved region of the protein.

The sequence for human GABRG1 protein was obtained from UNIPROT as accession number Q8N1C3. The downloaded Protein Data Bank structure (PDB: 6D6U) was used as a template to construct homology models using MODELLER (Fiser and Sali, 2003).

Twenty models were subjected to restrained energy minimization to relieve steric clashes between or among side chains. Stereochemical parameters were analyzed using PROCHECK (Laskowski et al., 1993) and PROSA (Wiederstein and Sippl, 2007). The final model was chosen based on a combination of the lowest energy function score (Dope) within the modeling program and model satisfaction of standard PROCHECK and PROSA criteria. Mutations were constructed and change of *in silico* free energy (ΔΔG) was calculated using the ICM mutagenesis program (www.molsoft.com) (Abagyan et al., 1994):

\[ ΔΔG = ΔG_{\text{misfolded}} - ΔG_{\text{unfolded}} \]

ΔG_{\text{unfolded}} refers to the sum of the energies attributed to the individual residues before the mutation, while ΔG_{\text{misfolded}} refers to the sum of the energies attributed to the individual residues after the mutation. A positive ΔΔG is proportional to the magnitude of the predicted destabilization effect on the protein caused by the point mutation.

**Enrichment analysis for the dominant variants**
A one-sided binomial test was performed to compare the observed number of damaging dominant variants within each gene with the expected number by the formula below (Jin et al., 2017), and calculated using the following formula:

\[
\text{Expected Counts}_i = N \times \frac{\text{Mutability}}{\sum_{\text{genes}} \text{Mutability}}
\]

where ‘i’ denotes the ‘ith’ gene; ‘N’ denotes the total number of damaging dominant variants; Mutability refers to the de novo probability in each gene. The p-value threshold after Bonferroni multiple testing correction is \(2.6 \times 10^{-6}\) (0.05/19,347).

**Gabrg1 mouse model and pain testing**

The Gabrg1 knock-in mouse model was generated using CRISPR/Cas9 (Henao-Mejia et al., 2016; Yang et al., 2013). In brief, a T7-sgRNA template was prepared by PCR (Henao-Mejia et al., 2016), incorporating the antisense guide sequence TAGGAAAATTATGAAGTTGA (from the mouse Gabrg1 gene target region) and then used for in vitro transcription and purification with the MEGASHortscript T7 Transcription Kit and MEGAClear Transcription Clean-Up Kit, respectively (both from Thermo Fisher Scientific). Cas9 mRNA (CleanCap, 5moU-modified) was purchased from TriLink Biotechnologies and the homology-directed repair (HDR) oligonucleotide (142 b including 65 b homology flanks was ordered from Integrated DNA Technologies as a phosphorothioate-protected Ultramer. All animal procedures were performed according to NIH guidelines and approved by the Yale IACUC. C57BL6/N strain mice were obtained from Charles River and cytoplasmic microinjections of the sgRNA, Cas9 mRNA and HDR oligo into single-cell embryos were performed by the Yale Genome Editing Center. DNA lysates of tissue biopsies from potential founder pups were screened by PCR amplification with the following primers (F5´-AGGAGGTCCAAATGCTGTT and R5´-GGGAAGGGCGGTAGATG), followed by diagnostic PstI digestion and sequencing confirmation.

Pain hypersensitivity was measured using complementary approaches. Nociceptive withdrawal thresholds of the hind paw and trigeminal nerve region were quantified using the Simplified Up-Down method (SUDO) (Bonin et al., 2014; Taylor et al., 2012). The experimental group consisted of male and female mice carrying homozygous C188W mutations in Gabrg1. Sex-matched WT mice were included in the control group. Mice were placed in a transparent Plexiglas cage atop a wire mesh and were free to move about. After 60 minutes of acclimation, withdrawal responses were assessed. To assess sensitivity in the trigeminal nerve regions, Von Frey filaments (Stoelting, USA) were applied perpendicularly to the region of interest. A positive reaction was noted if the animal exhibited a vigorous head retraction or rapid grooming of the muzzle region. The entire SUDO procedure was repeated twice per animal for each nerve region at 5 months of age. A Mann-Whitney test was performed to assess statistical significance of differences between groups. To assess nocifensive behavior to stimulation of the trigeminal area we also used a complementary modified version of a facial stimulation test (Bailey and Ribeiro-da-Silva, 2006). Mice were stimulated once using filament #7 (0.6 g) and the subsequent grooming response was video recorded. Positive (presence of a stimulus-associated grooming response) and negative responses (absence of grooming behavior) were scored as values of +1 or -1 value, respectively. Mice were
tested 3 times, on different days. Analysis of the videos was assessed by an experimenter blind to the animal’s genotype.

**Genome-wide association analysis**

Imputed genotype array data of 48,7395 samples were obtained from UK Biobank. Only SNPs which have a MAF > 0.05, have a missing genotype rate < 0.01 and passed the Hardy-Weinberg test (H-W p-value > 0.001) were considered for the analysis using plink (Chang et al., 2015). Subjects with self-report and genetically confirmed European ancestry were included (UK Biobank data filed 22006), whereas related subjects (relatedness > 0.1 by gcta64 (Yang et al., 2011)) were excluded. These filters yielded in 236 cases with TN (ICD10 code: G50.0 or G50.1) and 348,028 controls. A Multivariate Logistic Regression was performed using plink (Chang et al., 2015). The covariates included gender and the top 10 principle components. The Manhattan plot was generated using the R (3.4.1) package qqman.

**SUPPLEMENTARY REFERENCES**


(https://www.ichd-3.org/13-painful-cranial-neuropathies-and-other-facial-pains/13-1-
trigeminal-neuralgia/13-1-1-classical-trigeminal-neuralgia/; International Headache
Society).

nonpeptidergic afferents in an animal model of trigeminal neuropathic pain. Pain 153,
1311-1319.


Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., Del Angel, G., Levy-Moonshine,
confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr
Protoc Bioinformatics 43, 11 10 11-33.

Wang, C., Zhan, X., Bragg-Gresham, J., Kang, H.M., Stambolian, D., Chew, E.Y., Branham,
control of population stratification for sequence-based association studies. Nature
genetics 46, 409-415.


Ware, J.S., Samocha, K.E., Homsy, J., and Daly, M.J. (2015). Interpreting de novo Variation in
Human Disease Using denovolyzeR. Curr Protoc Hum Genet, 15.

framework for de novo mutation calling in parents-offspring trios. Bioinformatics 31,
1375-1381.


Wu, J., Yan, Z., Li, Z., Qian, X., Lu, S., Dong, M., Zhou, Q., and Yan, N. (2016). Structure of
the voltage-gated calcium channel Ca(v)1.1 at 3.6 Å resolution. Nature 537, 191-196.

generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated


structures of apo and antagonist-bound human Ca(v)3.1. Nature 576, 492-497.